Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study comparing the first line use effectiveness of Natalizumab in terms of healthcare resource use and impairment of work productivity and activity impairment with delayed use of Natalizumab

Next Previous
Trial Profile

A retrospective study comparing the first line use effectiveness of Natalizumab in terms of healthcare resource use and impairment of work productivity and activity impairment with delayed use of Natalizumab

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use

Most Recent Events

  • 19 Nov 2020 Results presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
  • 23 May 2020 New trial record
  • 20 May 2020 Results presented at the 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top